Santen Pharmaceutical CoSNPHY 87 Piotroski F-Score is 9 as of Jun. 25, 2026, which is 29% above its 10-year median of 7.00. GuruFocus rates SNPHY with a GF Score™ of 87/100 and a GF Value™ of $10.15 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 981 Drug Manufacturers companies, Santen Pharmaceutical Co ranks better than 99.9% on this metric.
Good Sign:
Piotroski F-Score is 9, indicates a very healthy situation.
The zones of discrimination were as such:
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Santen Pharmaceutical Co has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
The historical rank and industry rank for Santen Pharmaceutical Co's Piotroski F-Score or its related term are showing as below:
SNPHY'
s Piotroski F-Score Range Over the Past 10 Years
Min: 4 Med: 7 Max: 9
Current: 9
During the past 13 years, the highest Piotroski F-Score of Santen Pharmaceutical Co was 9. The lowest was 4. And the median was 7.
Santen Pharmaceutical Co (OTCPK:SNPHY) Piotroski F-Score Explanation
The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.
He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.
He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.
What he found was something that exceeded his most optimistic expectations.
Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.
Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).
Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.
Santen Pharmaceutical Co Piotroski F-Score Related Terms
Santen Pharmaceutical Co Piotroski F-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SNPHY vs LLY, JNJ, ABBV: Piotroski F-Score Comparison
For the Drug Manufacturers - General subindustry, Santen Pharmaceutical Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santen Pharmaceutical Co Piotroski F-Score vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Santen Pharmaceutical Co's Piotroski F-Score distribution charts can be found below:
* The bar in red indicates where Santen Pharmaceutical Co's Piotroski F-Score falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.
Profitability
Question 1. Return on Assets (ROA)
Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Santen Pharmaceutical Co's current Net Income (TTM) was 244.
==> Positive ==> Score 1.
Question 2. Cash Flow Return on Assets (CFROA)
Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.
Score 1 if positive, 0 if negative.
Santen Pharmaceutical Co's current Cash Flow from Operations (TTM) was 283.
==> Positive ==> Score 1.
Question 3. Change in Return on Assets
Compare this year's return on assets (1) to last year's return on assets.
Santen Pharmaceutical Co's return on assets of this year was 0.08876728. Santen Pharmaceutical Co's return on assets of last year was 0.08245165.
==> This year is higher. ==> Score 1.
Question 4. Quality of Earnings (Accrual)
Compare Cash flow return on assets (2) to return on assets (1)
Santen Pharmaceutical Co's gearing of this year was 0. Santen Pharmaceutical Co's gearing of last year was 0.
==> This year is lower or equal to last year. ==> Score 1.
Question 6. Change in Working Capital (Liquidity)
Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.
Score 1 if this year's current ratio is higher, 0 if it's lower
Santen Pharmaceutical Co's current ratio of this year was 2.60342692. Santen Pharmaceutical Co's current ratio of last year was 2.58300162.
==> This year's current ratio is higher. ==> Score 1.
Question 7. Change in Shares in Issue
Compare the number of shares in issue this year, to the number in issue last year.
Score 0 if there is larger number of shares in issue this year, 1 otherwise.
Santen Pharmaceutical Co's number of shares in issue this year was 328.374. Santen Pharmaceutical Co's number of shares in issue last year was 349.694.
==> There is smaller number of shares in issue this year, or the same. ==> Score 1.
Efficiency
Question 8. Change in Gross Margin
Compare this year's gross margin (Gross Profit divided by sales) to last year's.
Score 1 if this year's gross margin is higher, 0 if it's lower.
Santen Pharmaceutical Co's gross margin of this year was 0.58099166. Santen Pharmaceutical Co's gross margin of last year was 0.57009061.
==> This year's gross margin is higher. ==> Score 1.
Question 9. Change in asset turnover
Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.
Score 1 if this year's asset turnover ratio is higher, 0 if it's lower
Santen Pharmaceutical Co's asset turnover of this year was 0.6994006. Santen Pharmaceutical Co's asset turnover of last year was 0.68406256.
==> This year's asset turnover is higher. ==> Score 1.
Evaluation
Piotroski F-Score
=
Que. 1
+
Que. 2
+
Que. 3
+
Que. 4
+
Que. 5
+
Que. 6
+
Que. 7
+
Que. 8
+
Que. 9
=
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
+
1
=
9
Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3
Santen Pharmaceutical Co has an F-score of 9. It is a good or high score, which usually indicates a very healthy situation.
Santen Pharmaceutical Co (SNPHY) has a Piotroski F-Score of 9 as of Jun. 25, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Santen Pharmaceutical Co and its competitors. This is 29% above median its historical median of 7.00. Over the past decade, Santen Pharmaceutical Co's Piotroski F-Score has ranged from 4.00 to 9.00. According to the industry distribution chart, Santen Pharmaceutical Co ranks #1 out of 981 companies in the Drug Manufacturers industry, placing it in the top 0.099999999999994%.
Is Santen Pharmaceutical Co's Piotroski F-Score too high?
Santen Pharmaceutical Co's current Piotroski F-Score of 9 is 29% above median its 10-year median of 7.00. Over the past 10 years, this metric has ranged from a low of 4.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Santen Pharmaceutical Co's value of 9 is 80% above this industry median. Based on the distribution chart, Santen Pharmaceutical Co ranks #1 out of 981 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Santen Pharmaceutical Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Santen Pharmaceutical Co's Piotroski F-Score compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Santen Pharmaceutical Co ranks #1 out of 981 companies for Piotroski F-Score. This places Santen Pharmaceutical Co in the top 0% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Santen Pharmaceutical Co's value of 9 is 80% above this benchmark. Historically, Santen Pharmaceutical Co's own Piotroski F-Score has ranged from 4.00 to 9.00 over the past decade. While the company's 10-year median is 7.00 vs. the industry median of 5.00, Santen Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 981 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Santen Pharmaceutical Co's current Piotroski F-Score of 9 is 80% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Santen Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Santen Pharmaceutical Co's current Piotroski F-Score is 9, which is 29% above median its own 10-year median of 7.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santen Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Santen Pharmaceutical Co (SNPHY) is currently considered Modestly Overvalued. The stock's GF Value™ is $10.15, compared to a current price of $12.36 — trading 21.8% above its estimated fair value. The current Piotroski F-Score is 9, which is 29% above median its 10-year median of 7.00 and 80% above the Drug Manufacturers industry median of 5.00. Santen Pharmaceutical Co's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Santen Pharmaceutical Co (SNPHY), the current Piotroski F-Score is 9 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santen Pharmaceutical Co (SNPHY) Overvalued in 2026?
Based on GuruFocus' analysis, Santen Pharmaceutical Co stock appears to be overvalued.
The current stock price of $12.36 is trading 21.8% above its estimated GF Value™ of $10.15.
GuruFocus considers Santen Pharmaceutical Co to be Modestly Overvalued.
Key valuation signals for SNPHY:
Piotroski F-Score: 9 (29% above median its 10-year median of 7.00)
GF Value™: $10.15 vs. price of $12.36 (21.8% above fair value)
Industry Position: 80% above the Drug Manufacturers median (#1 of 981)
No single metric tells the full story. See the SNPHY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santen Pharmaceutical Co Ltd is a drug manufacturing company that focuses on ophthalmic products. The company provides a wide range of prescription and over-the-counter eye care products, including treatments for glaucoma, dry eye, and allergies. It also develops surgical and diagnostic devices related to eye care.
87GF Score
Get the complete analysis for SNPHY
Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNPHY has been successfully added to your 
